CureVac receives 13m [euro] to boost mRNA cancer vaccines.

CureVac GmbH banked 13 million [euro] (US$17.7 million) in a second closing of its Series B round, taking the total value of the transaction to 35 million [euro] and accelerating the development of its pipeline of mRNA-based cancer vaccines.

There was no change in the Tubingen, Germany-based company's investor roster, however. The funding came from DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG, both Heidelberg, Germany-based funds owned by the family of SAP AG co-founder Dietmar Hopp, one of the most active investors in Germany biotechnology at present.

Hopp's funds had invested 22 million [euro] in a first closing of the round, disclosed in …